HK1111995A1 - Substituted imidazole compounds as ksp inhibitors - Google Patents

Substituted imidazole compounds as ksp inhibitors

Info

Publication number
HK1111995A1
HK1111995A1 HK08107126.4A HK08107126A HK1111995A1 HK 1111995 A1 HK1111995 A1 HK 1111995A1 HK 08107126 A HK08107126 A HK 08107126A HK 1111995 A1 HK1111995 A1 HK 1111995A1
Authority
HK
Hong Kong
Prior art keywords
imidazole compounds
substituted imidazole
ksp inhibitors
ksp
inhibitors
Prior art date
Application number
HK08107126.4A
Other languages
English (en)
Inventor
Paul A Barsanti
Yi Xia
Weibo Wang
Kris G Mendenhall
Liana M Lagniton
Savithri Ramurthy
Megan C Phillips
Sharadha Subramanian
Rustum Boyce
Nathan M Brammeier
Ryan Constantine
David Duhl
Annette O Walter
Tinya J Abrams
Paul A Renhowe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1111995A1 publication Critical patent/HK1111995A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK08107126.4A 2005-08-09 2008-06-26 Substituted imidazole compounds as ksp inhibitors HK1111995A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70690105P 2005-08-09 2005-08-09
PCT/US2006/031129 WO2007021794A1 (en) 2005-08-09 2006-08-09 Substituted imidazole compounds as ksp inhibitors

Publications (1)

Publication Number Publication Date
HK1111995A1 true HK1111995A1 (en) 2008-08-22

Family

ID=37421032

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08107126.4A HK1111995A1 (en) 2005-08-09 2008-06-26 Substituted imidazole compounds as ksp inhibitors

Country Status (20)

Country Link
US (1) US7626040B2 (es)
EP (1) EP1912972B1 (es)
JP (1) JP4975745B2 (es)
KR (1) KR20080036611A (es)
CN (1) CN101253167A (es)
AR (1) AR056025A1 (es)
AT (1) ATE526324T1 (es)
AU (1) AU2006279991B2 (es)
BR (1) BRPI0614547A2 (es)
CA (1) CA2618747A1 (es)
ES (1) ES2374449T3 (es)
GT (1) GT200600366A (es)
HK (1) HK1111995A1 (es)
MY (1) MY147188A (es)
PE (1) PE20070352A1 (es)
PL (1) PL1912972T3 (es)
PT (1) PT1912972E (es)
RU (1) RU2413721C9 (es)
TW (1) TW200800951A (es)
WO (1) WO2007021794A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009005071A (es) * 2006-11-13 2009-05-25 Novartis Ag Compuestos de pirazol y triazol sustituidos como inhibidores de ksp.
BRPI0806264A2 (pt) * 2007-01-05 2011-08-30 Novartis Ag derivados ciclizados como inibidores de eg-5
US8796460B2 (en) 2007-10-19 2014-08-05 Mercky Sharp & Dohme Corp. Compounds for inhibiting KSP kinesin activity
US8252832B2 (en) * 2007-12-14 2012-08-28 Novartis Ag Kinesin inhibitors as cancer therapeutics
MX2012011910A (es) 2010-04-15 2012-11-29 Novartis Ag Compuestos de triazol como inhibidores de ksp.
CN105451773A (zh) * 2013-03-15 2016-03-30 诺华股份有限公司 细胞增殖抑制剂及其缀合物
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
RU2698697C2 (ru) * 2013-12-23 2019-08-29 Байер Фарма Акциенгезельшафт Конъюгаты связующего (ADC) с ингибиторами KSP
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
MX2017017172A (es) * 2015-06-22 2018-02-23 Bayer Pharma AG Conjugados de ligador-principio activo (adcs) y conjugados de ligador-profarmaco (apdcs) con grupos enzimaticamente escindibles.
CA3027445A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
EP3558387B1 (de) 2016-12-21 2021-10-20 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
KR102556826B1 (ko) 2016-12-21 2023-07-18 바이엘 파마 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc)
SG11202012608VA (en) 2018-06-18 2021-02-25 Bayer Ag Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile
CN109481436A (zh) * 2018-08-21 2019-03-19 广东医科大学 血栓素a2合成酶抑制剂奥扎格雷在制备治疗吸烟所致肺癌药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
EP0946587A2 (en) 1996-12-16 1999-10-06 Fujisawa Pharmaceutical Co., Ltd. New amide compounds
US6117940A (en) 1997-10-17 2000-09-12 Mjalli; Adnan M. M. Amino-ketone solid support templates
DE69921124T2 (de) * 1998-06-12 2005-11-10 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Imidazolderivate und ihre verwendung als somatostatin rezeptorliganden
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
EP1226129B1 (en) * 1999-10-27 2006-05-24 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
WO2001083575A1 (en) 2000-05-02 2001-11-08 Advanced Syntech, Llc A Kentucky Limited Liability Corporation A novel solid support template for preparation of highly functionalized heterocycle compounds
AU7909801A (en) * 2000-08-01 2002-02-13 Sod Conseils Rech Applic Imidazolyl derivatives
DE10211770A1 (de) 2002-03-14 2003-10-02 Boehringer Ingelheim Pharma Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US7026312B2 (en) 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
WO2004071448A2 (en) 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
EP1620092A4 (en) * 2003-05-07 2008-04-16 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
JP2007500746A (ja) * 2003-05-15 2007-01-18 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2005100322A1 (en) 2004-04-14 2005-10-27 Pfizer Limited Sulphur-linked imidazole compounds for the treament of hiv
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
CA2571002A1 (en) * 2004-06-18 2006-01-05 Chiron Corporation N-(1-(1-benzyl-4-phenyl-1h-imidazol-2-yl)-2,2-dimethylpropyl)benzamide derivatives and related compounds as kinesin spindle protein (ksp) inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
CA2618747A1 (en) 2007-02-22
AU2006279991B2 (en) 2011-09-29
GT200600366A (es) 2007-05-10
JP4975745B2 (ja) 2012-07-11
ATE526324T1 (de) 2011-10-15
PE20070352A1 (es) 2007-05-30
US7626040B2 (en) 2009-12-01
KR20080036611A (ko) 2008-04-28
PL1912972T3 (pl) 2012-02-29
ES2374449T3 (es) 2012-02-16
RU2008108939A (ru) 2009-09-20
RU2413721C9 (ru) 2011-05-20
CN101253167A (zh) 2008-08-27
RU2413721C2 (ru) 2011-03-10
AU2006279991A1 (en) 2007-02-22
US20070037853A1 (en) 2007-02-15
WO2007021794A1 (en) 2007-02-22
JP2009504664A (ja) 2009-02-05
AR056025A1 (es) 2007-09-12
PT1912972E (pt) 2012-01-06
EP1912972B1 (en) 2011-09-28
TW200800951A (en) 2008-01-01
EP1912972A1 (en) 2008-04-23
MY147188A (en) 2012-11-14
BRPI0614547A2 (pt) 2011-03-29

Similar Documents

Publication Publication Date Title
HUS1900033I1 (hu) Szubsztituált enaminokarbonil vegyületek
HK1111995A1 (en) Substituted imidazole compounds as ksp inhibitors
IL185185A0 (en) Azolylacylguanidines as ??-secretase inhibitors
IL205159A0 (en) Imidazole compounds
IL189194A0 (en) Substituted benzimidazoles as kinase inhibitors
IL190450A0 (en) Substituted pyrazole compounds
EP1790650B1 (en) NEW SUBSTITUTED IMIDAZOLE DERIVATIVES
EP1847531A4 (en) PYRAZOLE DERIVATIVE
EP1778693A4 (en) AS KINASEINHIBITORS USEFUL COMPOUNDS OF TRICYCLIC HETEROARYL
IL187279A0 (en) Hydantoin compounds
HK1117826A1 (en) Benzimidazole compound
IL198471A0 (en) Substituted pyrazole and triazole compounds as ksp inhibitors
ZA200900625B (en) Substituted 1-(azolin-2-yl)-amino-2-aryl-1-hetaryl-ethane compounds
IL184559A0 (en) Imidazole derivatives
ZA200802786B (en) Substituted pyrazole compounds
ZA200800506B (en) Substituted benzimidazoles as kinase inhibitors
ZA200708803B (en) Benzimidazole compound
ZA200901570B (en) Substituted azolin-2-YL-amino compounds
EP1998776A4 (en) MACRO-HETEROCYL COMPOUNDS CONTAINING PYRIDINE AS KINASE INHIBITORS
ZA200703075B (en) Imidazole compound
AU2006900914A0 (en) Imidazole compounds
EP1940411A4 (en) MACROHETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
PL1956027T3 (pl) Związek karbapenemowy

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150809